Pancreatic cancer - Pilar Navarro and Fernando Burdío
Basic/translational research | Clinical research
Institute of Biomedical Research of Barcelona (IIBB-CSIC) / Associated Unit Hospital del Mar Research Institute (HMRI)
·Barcelona ·

This group includes two teams that carry out their research at the Hospital del Mar:

The group of “Ablation therapies in oncologic surgery“directed by Fernando BurdíoThe primary objective of the scientific production and technological innovation in the field of applications of high frequency currents in the generation of heat in biological tissues, aimed at local cell destruction, minimally invasiveof pathological tissues, especially (but not exclusively) of human neoplasms.

https://www.imim.cat/programesrecerca/cancer/es_thipertermia.html

The “Molecular Targets of Cancer” group led by Pilar Navarro (IIBB-CSIC/ Associated Unit Hospital del Mar Research Institute (HMRI)) has been exploring the molecular mechanisms of pancreatic cancer for more than 20 years with the aim of identifying new targets to improve early diagnosis and treatment of this tumor. For this purpose, we use cell and molecular biology techniques, in vitro functional assays and preclinical animal models that recapitulate the human pancreatic tumor and its microenvironment.

Our most recent studies are focused on Galectin-1. as a biomarker and new therapeutic immune checkpoint (Martínez-Bosch N et al. Oncotarget 2018; Martínez-Bosch N et al. Cancer Res. 2014; Orozco CA et al. PNAS 2018; Navarro P et al. Clin Cancer Res. 2020), sAXL as an early biomarker of pancreatic cancer and differential diagnosis of chronic pancreatitis (Martínez-Bosch N et al. eBioMed 2022) and the study of translational control as a new mechanism of gene reprogramming in this cancer (Ortiz-Zapater E et al. Nat Med. 2012; Villanueva E et al. Nat Comm. 2017; Jungfleisch J et al. Genome Res. 2017).

 

Main publications in pancreatic cancer:

  1. Martínez-Bosch N, Cristóbal H, Iglesias M, Gironella M, Barranco L, Visa L, Calafato D, Jiménez-Parrado S, Earl J, Carrato A, Manero-Rupérez N, Moreno M, Morales A, Guerra C, Navarro P, García de Frutos P. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. EBioMedicine 2022 Jan;75:103797. doi: 10.1016/j.ebiom.2021.103797. 
  2. Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 2018 Apr 17;115(16):E3769-E3778. doi: 10.1073/pnas.1722434115. 
  3. Ortiz-Zapater E, Pineda D, Martínez-Bosch N, Fernández-Miranda G, Iglesias M, Alameda F, Moreno M, Eliscovich C, Eyras E, Real FX, Méndez R, Navarro P. Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med. 2011 Dec 4;18(1):83-90. doi: 10.1038/nm.2540.
Pilar Navarro Medrano
Fernando Burdío

Principal Investigator

Group members

  • Pilar Navarro Medrano
  • Fernando Burdío Pinilla
  • Neus Martinez Bosch
  • Luis Barranco Priego
  • Laura Visa
  • Benedetto Ielpo
  • Patricia Sánchez-Velázquez
  • Mª Evangelina Patriarca Amiano
  • Mar Iglesias
  • Inés Molejón
  • Nuria Vázquez Bellón
More information

Other groups

See all groups